Table Graph
   

antiviral and associated therapy - versus control - for COVID 19 all comers pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.73 [0.52, 1.03]< 10%1 study (2/-)96.4 %NAnot evaluable crucial-
deaths 0.55 [0.37, 0.84]< 10%2 studies (5/-)99.7 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.55 [0.36, 0.84]< 10%1 study (1/-)99.7 %NAnot evaluable crucial-
clinical deterioration 2.07 [0.06, 66.79]< 10%1 study (1/-)34.3 %NAnot evaluable important-
clinical improvement 1.29 [1.12, 1.49]> 10%2 studies (2/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.25 [0.21, 7.62]> 10%1 study (1/-)59.5 %NAnot evaluable important-
clinical improvement (28-day) 1.35 [1.03, 1.76]> 10%1 study (1/-)98.7 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.29 [1.12, 1.49]> 10%1 study (1/-)100.0 %NAnot evaluable important-
hospitalization 0.29 [0.08, 1.07]< 10%1 study (1/-)96.8 %NAnot evaluable important-
mechanical ventilation 2.07 [0.06, 66.79]< 10%1 study (1/-)34.3 %NAnot evaluable important-
mechanical ventilation (time to event analysis only) 0.43 [0.16, 1.14]< 10%1 study (-/1)95.5 %NAnot evaluable important-
viral clearance 0.18 [0.01, 4.75]> 10%1 study (2/-)15.7 %NAnot evaluable important-
viral clearance (time to event analysis only) 0.82 [0.36, 1.87]> 10%1 study (1/-)31.9 %NAnot evaluable important-
viral clearance by day 14 0.18 [0.01, 4.75]> 10%1 study (1/-)15.7 %NAnot evaluable important-
viral clearance by day 7 0.58 [0.14, 2.48]> 10%1 study (1/-)23.3 %NAnot evaluable important-
ICU admission 5.43 [0.21, 139.89]< 10%1 study (1/-)15.7 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.72 [0.54, 0.96]< 10%1 study (1/-)98.8 %NAnot evaluable important-
adverse events 1.92 [0.31, 12.05]< 10%1 study (1/-)24.3 %NAnot evaluable non important-
deep vein thrombosis 0.64 [0.23, 1.81]< 10%1 study (1/-)80.0 %NAnot evaluable non important-
elevated liver enzymes 0.67 [0.38, 1.18]< 10%1 study (1/-)91.8 %NAnot evaluable non important-
hyperbilirubinemia 0.84 [0.30, 2.34]< 10%1 study (1/-)62.9 %NAnot evaluable non important-
pulmonary embolism 0.96 [0.19, 4.80]< 10%1 study (1/-)51.7 %NAnot evaluable non important-
renal impairment 1.02 [0.64, 1.61]< 10%1 study (1/-)47.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons